CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for Casgevy, a therapy for the rare blood diseases transfusion-dependent beta-thalassemia and sickle cell disease.

Though that was an important milestone for the biotech, CRISPR Therapeutics remains unprofitable, and it is unlikely to launch another product in the next couple of years. In light of all that, is it worth investing in CRISPR Therapeutics today?

Developing gene-editing therapies is difficult, but commercializing them is its own challenge. To administer Casgevy, physicians first need to collect the patient's cells, which are edited and reinserted into them via a stem cell transplant. These procedures must be performed in authorized treatment centers. CRISPR Therapeutics originally created Casgevy, but co-markets it with the much larger Vertex Pharmaceuticals.

Continue reading

Source Fool.com